(S)-N-Glycidylphthalimide - CAS 161596-47-0
Catalog: |
BB011761 |
Product Name: |
(S)-N-Glycidylphthalimide |
CAS: |
161596-47-0 |
Synonyms: |
1H-Isoindole-1,3(2H)-dione, 2-[(2S)-2-oxiranylmethyl]-; 1H-Isoindole-1,3(2H)-dione, 2-(oxiranylmethyl)-, (S)-; 1H-Isoindole-1,3(2H)-dione, 2-[(2S)-oxiranylmethyl]-; 2-[(2S)-2-Oxiranylmethyl]-1H-isoindole-1,3(2H)-dione; (S)-2-(Oxiran-2-ylmethyl)-1H-isoindole-1,3(2H)-dione; (S)-2-(Oxiran-2-ylmethyl)isoindoline-1,3-dione; (S)-2-[(Oxiranyl)methyl]isoindole-1,3-dione; (S)-Glycidyl Phthalimide; (S)-N-(2,3-Epoxypropan-1-yl)phthalimide; (S)-N-(2,3-Epoxypropyl)phthalimide; (S)-N-Giycidylphthalimide; 2-[(S)-2-Oxiranylmethyl]-1H-isoindol-1,3(2H)-dione; N-((2S)-Oxiran-2-ylmethyl)phthalimide; N-(S)-Glycidylphthalimide; N-[(+)-Glycidyl]phthalimide; N-[(S)-(+)-Glycidyl]phthalimide; (S)-(+)-N-(2,3-Epoxypropyl)phthalimide |
IUPAC Name: | 2-[[(2S)-oxiran-2-yl]methyl]isoindole-1,3-dione |
Description: | (S)-N-Glycidylphthalimide is an impurity of Rivaroxaban, a factor Xa (FXa) inhibitor used for the prevention and treatment of thromboembolic disorders. |
Molecular Weight: | 203.19 |
Molecular Formula: | C11H9NO3 |
Canonical SMILES: | C1C(O1)CN2C(=O)C3=CC=CC=C3C2=O |
InChI: | InChI=1S/C11H9NO3/c13-10-8-3-1-2-4-9(8)11(14)12(10)5-7-6-15-7/h1-4,7H,5-6H2/t7-/m0/s1 |
InChI Key: | DUILGEYLVHGSEE-ZETCQYMHSA-N |
Boiling Point: | 347.4±15.0°C at 760 mmHg |
Melting Point: | 101-103°C |
Purity: | ≥95% |
Density: | 1.446±0.06 g/cm3 |
Solubility: | Soluble in Chloroform (Slightly), Ethyl Acetate (Slightly) |
Appearance: | White Solid |
Storage: | Store at 2-8°C under inert atmosphere |
MDL: | MFCD04973350 |
LogP: | 0.61930 |
GHS Hazard Statement: | H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin] |
Precautionary Statement: | P201, P202, P261, P272, P280, P281, P302+P352, P305+P351+P338, P308+P313, P310, P321, P333+P313, P363, P405, and P501 |
Signal Word: | Danger |
Publication Number | Title | Priority Date |
CN-112159402-A | Preparation method of rivaroxaban | 20201028 |
CN-111675705-A | Preparation method of 4- (4-aminophenyl) morpholine-3-one derivative | 20200811 |
CN-111983055-A | Method for separating and measuring rivaroxaban intermediate related substances by using HPLC (high performance liquid chromatography) | 20200728 |
CN-111721858-A | Method for determining genotoxic impurities in rivaroxaban | 20200603 |
WO-2021098840-A1 | SULFONYLUREA RING SUBSTITUTED MONOCYCLIC β-LACTAM ANTIBIOTICS | 20191122 |
Complexity: | 291 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 1 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 203.058243149 |
Formal Charge: | 0 |
Heavy Atom Count: | 15 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 0 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 203.058243149 |
Rotatable Bond Count: | 2 |
Topological Polar Surface Area: | 49.9 Å2 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 1.2 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Carbonyl Compounds
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS